- •
A substantial body of evidence points to key role for microbiome-host interactions in the pathogenesis of inflammatory bowel disease (IBD).
- •
Data from animal models support potent antiinflammatory effects for several specific commensal/probiotic strains.
- •
Well-designed studies of probiotics in IBD in humans remain scanty.
- •
Available evidence supports a role for probiotics in pouchitis and mild/moderate ulcerative colitis but not in Crohn disease.
- •
Novel approaches to the modulation of the microbiota in
Probiotics in Inflammatory Bowel Disease
Section snippets
Key points
Probiotics: definition
Probiotics are defined as live microbial food ingredients that, when ingested in adequate amounts, alter the microflora and confer a health benefit to the host.12, 13, 14 For now the definition of a probiotic demands that the organisms included in the preparation be live and assumes that any biological or clinical effects depend on bacterial viability; studies showing (albeit in in vitro or animal models) that dead organisms or bioactive molecules produced by bacteria, such as proteins,
Probiotics: mechanisms of action relevant to inflammatory bowel disease
Many probiotics are derived from the commensal microbiota in the healthy human gut; their properties, understandably, mimic those of the homeostatic effects of the intact microbiota, and several are relevant to IBD.
First and foremost, a substantial literature attests to the antiinflammatory effects of probiotics which, in turn, reflect the immune tolerance that exists between the host and its microbiota. Studies show that probiotics alter the mucosal immune system through a process mediated by
Probiotics in the management of inflammatory bowel disease
The impact of probiotics on UC, Crohn disease, and pouchitis has been the subject of several systematic reviews and meta-analyses.59, 60, 61, 62, 63, 64, 65, 66, 67, 68 Before discussing the conclusions of these studies, several issues need to be addressed. First, combining diverse species and strains in a single analysis suggests that they are homogeneous, which they are not; second, populations of patients with UC or Crohn disease are remarkably heterogeneous; and, third, when critically
Probiotics: quality control
It is critical, at this juncture, to emphasize that no 2 probiotics are the same, despite commercial claims to the contrary. To be effective at their likely sites of action, probiotics need to be able to survive stomach acid, bile, and digestive enzymes and to be viable for the duration of their shelf lives; many products on supermarket shelves do not meet even these most basic standards. Many more have never been subjected to clinical evaluation in any disease category and base their claims on
Probiotics: safety
Probiotics are generally regarded as safe.103, 104, 105 Furthermore, their record in patients with IBD, a population that may be susceptible to intestinal translocation and, thus, systemic sepsis, has been reassuring. Of concern was a case of systemic dissemination leading to sepsis in a newborn given E coli strain Nissle 1917 for viral gastroenteritis.106 Although probiotics and prebiotics have a long safety record, there may still be risks in certain disease populations. Particular vigilance
Probiotics: the future
Despite the existence of a compelling narrative that supports a critical role for the gut microbiota in IBD and a large volume of laboratory data showing impressive beneficial effects of various bacterial strains in animal models of IBD, the IBD probiotic clinical portfolio is far from convincing. Several factors may contribute to this disappointment: the limitations of animal models, differences in probiotic dosage, and a failure to account for the multiple phenotypes that IBD manifests in
Summary/discussion
Despite the undoubted role of the microbiota in IBD and the attractiveness of probiotics as a therapeutic intervention, the extant literature on these therapies is far from impressive and has many limitations. Furthermore, generic issues relating to quality control continue to bedevil what is essentially a lightly regulated market. Many probiotic products on sale in supermarkets and pharmacies have not been adequately tested for the viability of their bacteria over the durations of their
References (112)
- et al.
The microbiome in inflammatory bowel disease: current status and the future ahead
Gastroenterology
(2014) - et al.
Manipulation of the microbiota for treatment of IBS and IBD–challenges and controversies
Gastroenterology
(2014) - et al.
Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: pitfalls and promises from a first meta-analysis
Transplant Proc
(2016) - et al.
In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects
Int J Food Microbiol
(2010) - et al.
Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition
Gastroenterology
(2004) - et al.
Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains
Vaccine
(2000) - et al.
Bifidobacterium infantis suppression of Peyer's patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+CD25+ T cell numbers
Cell Immunol
(2013) - et al.
Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells
J Biol Chem
(2002) Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens
FEMS Microbiol Rev
(2004)Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics
Gastroenterology
(2004)
Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice
J Nutr
Potential probiotic characteristics of Lactobacillus and Enterococcus strains isolated from traditional dadih fermented milk against pathogen intestinal colonization
J Food Prot
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression
Neuroscience
Saccharomyces boulardii does not prevent relapse of Crohn's disease
Clin Gastroenterol Hepatol
Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double blind randomized placebo controlled clinical trial
J Crohns Colitis
Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality
Gastroenterol Clin North Am
A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis
J Crohns Colitis
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
Lancet
Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment
Gastroenterology
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gastroenterology
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial
Gastroenterology
Complementary and alternative medicines used by patients with inflammatory bowel diseases
Gastroenterology
Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease
World J Gastroenterol
Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches
Gastroenterology
Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases
J Gastroenterol
Targeting the microbiome in inflammatory bowel disease: critical evaluation of current concepts and moving to new horizons
Dig Dis
Therapeutic manipulation of the microbiome in IBD: current results and future approaches
Curr Treat Options Gastroenterol
Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease
Aliment Pharmacol Ther
Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial
Gastroenterology
Role of endogenous microbiota, probiotics and their biological products in human health
Nutrients
Guidelines for the evaluation of probiotics in food. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food
Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
Nat Rev Gastroenterol Hepatol
Prebiotics and synbiotics in ulcerative colitis
Scand J Gastroenterol
Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain
Pediatr Res
Natural killer cell activities of synbiotic Lactobacillus casei ssp. casei in conjunction with dextran
Clin Exp Immunol
Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities
Nutr Cancer
Adhesion of lactic acid bacteria to caco-2 cells and their effect on cytokine secretion
Microbiol Immunol
Live lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression
Infect Immun
The gut microbiota and its role in the development of allergic disease: a wider perspective
Clin Exp Allergy
Portrait of an immunoregulatory Bifidobacterium
Gut Microbes
Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance
Gut
Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius
Immunology
Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans
Am J Physiol Gastrointest Liver Physiol
Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria
FEMS Immunol Med Microbiol
Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells
Gut
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut
Gut Microbes
Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation
PLoS Pathog
Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina propria requires retinoic acid-dependent and independent mechanisms
PLoS One
Genome analysis and characterisation of the exopolysaccharide produced by Bifidobacterium longum subsp. longum 35624™
PLoS One
The surface-associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses
Appl Environ Microbiol
Cited by (125)
In inflammatory bowel disease and extraintestinal manifestations: What role does microbiome play?
2023, Engineered RegenerationAlginate-based drug carrier systems to target inflammatory bowel disease: A review
2023, International Journal of Biological MacromoleculesHighlights on two decades with microbiota and inflammatory bowel disease from etiology to therapy
2023, Transplant ImmunologySustainable materials and infrastructures for the food industry
2023, Sustainable Development and Pathways for Food Ecosystems: Integration and SynergiesBacillus amyloliquefaciens protects Nile tilapia against Aeromonas hydrophila infection and alleviates liver inflammation induced by high-carbohydrate diet
2022, Fish and Shellfish ImmunologyCitation Excerpt :Consistently, we demonstrated that B. amyloliquefaciens SS1 could effectively stimulate the respiratory burst activity of head kidney macrophages and increased the resistance against A. hydrophila infection. Numerous evidences suggested that probiotics could modulate anti-inflammatory response by secreting some specific metabolite [23,24]. Harry Sokol has revealed that Faecalibacterium prausnitzii or its supernatant exhibited anti-inflammatory effects by abolishing NF-κB activation and IL-1β production in 2,4,6-trinitrobenzenesulphonic acid-induced colitis mice [25].
Disclosure: E.M.M. Quigley holds stock in and patents with Alimentary Health and has served as an advisor/consultant to Alimentary Health, Biocodex, Bionutrec, Commonwealth Laboratories, Danone, Pharmasierra, Procter and Gamble, Salix, and Yakult. B.P. Abraham has no relevant disclosures.